OTSUKA (OTSKF)
Healthcare · market cap $38.8B · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
- 2027-02-24 (est.)Phase 2 · Bedaquiline (B)imp 7/10
- 2027-03-13 (est.)Phase 2 · Sibeprenlimabimp 7/10
- 2027-05-15 (est.)Phase 2 · IRL757imp 7/10
- 2027-05-27 (est.)Phase 3 · Centanafadine XRimp 9/10
- 2027-08-15 (est.)Phase 3 · EB-1020 (Centanafadine) low doseimp 9/10
- 2027-09-15 (est.)Phase 3 · OPC-34712FUM/Brexpiprazole fumarateimp 9/10
- 2027-11-01 (est.)Phase 3 · JNT-517imp 9/10
| Asset | Phase | Indication |
|---|---|---|
| Medium Dose-VIS649 | Phase 2 | Immunoglobulin A Nephropathy |
| Paroxetine CR | Phase 3 | Depressive Disorder |
| OPB-31121 phase2 | Phase 2 | Hepatocellular Carcinoma |
| Centanafadine XR | Phase 3 | Attention-deficit/Hyperactivity Disorder |
| Graft versus Host Disease prevention (GVHD prophylaxis) | Phase 2 | Hematological Malignancies |
| Brexpiprazole, OPC-34712 | Phase 3 | Agitation Associated With |
| Venlafaxine XR | Phase 3 | Depressive Disorder |
| Clofazimine | Phase 2 | Tuberculosis, Multidrug-Resistant |
| High Dose-VIS649 | Phase 2 | Immunoglobulin A Nephropathy |
| OCV-501 | Phase 2 | Acute Myeloid Leukemia |
| JNT-517 Tablet | Phase 3 | Phenylketonuria (PKU) |
| Sodium hyaluronate ophthalmic solution | Phase 2 | Keratoconjunctival Epithelial Disorder |
| Delamanid + Bedaquiline + OPC-167832 | Phase 2 | Pulmonary TB |
| centanafadine capsule | Phase 3 | Attention Deficit/Hyperactivity Disorder |
| Probucol | Phase 3 | Hyperlipidemia |
| Centanafadine Hydrochloride | Phase 3 | Attention-Deficit/Hyperactivity Disorder |
| Tolvaptan Oral Tablet | Phase 3 | Syndrome of Inappropriate Antidiuretic Hormone Secretion |
| OPB-31121 | Phase 2 | Hepatocellular Carcinoma |
| OPC-64005 | Phase 2 | Adult Attention Deficit Hyperactivity Disorder |
| OPC-41061 (Tolvaptan) | Phase 3 | Cardiac Edema |
Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
- SEC filings — EDGAR filings for OTSKF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.
